GHRP-6 Acetate

Comprehensive Research Analysis - Growth Hormone Releasing Peptide for GH Secretion

Classification: Growth Hormone Secretagogue, Ghrelin Receptor Agonist Amino Acid Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ Chemical Formula: C₄₆H₅₆N₁₂O₆ Molecular Weight: 873.01 Da (873.03 g/mol as acetate salt) Research Status: Investigational; Clinical Trials Completed (Not FDA-Approved) WADA Status: Prohibited S2 (Peptide Hormones - Banned At All Times)

1. Executive Summary

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic met-enkephalin analogue that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R). It stimulates pulsatile GH release from the anterior pituitary, mimicking natural GH secretion patterns. GHRP-6 contains unnatural D-amino acids, making it more stable and resistant to proteolytic degradation than natural peptides.

Key Characteristic: GHRP-6 causes the strongest hunger increases among all growth hormone releasing peptides, with users reporting "agonizing hunger" within 15–30 minutes of injection.

Clinical Trials: Phase I pharmacokinetic study in nine male healthy volunteers demonstrated GH-releasing activity via IV, subcutaneous, intranasal, and oral routes. Pediatric study showed GH-releasing effects at 300 mcg/kg oral dosing in children with short stature.

Goal Relevance:

• Enhance muscle growth and strength for bodybuilding or athletic performance
• Support recovery from injuries or surgeries by promoting tissue repair
• Boost energy levels and overall vitality through hormone optimization
• Improve appetite and weight gain for individuals with difficulty maintaining weight
• Aid in managing short stature in children by stimulating growth hormone release
• Support anti-aging efforts by mimicking natural growth hormone secretion patterns

2. Chemical Structure & Composition

Molecular Weight: 873.01 Da (free base); 873.03 g/mol (acetate salt) Formula: C₄₆H₅₆N₁₂O₆ CAS Number: 87616-84-0 (free base)

Amino Acid Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂

• L-Histidine, D-Tryptophan, L-Alanine, L-Tryptophan, D-Phenylalanine, L-Lysine with C-terminal amidation

Structure: Single, non-glycosylated hexapeptide (six amino acids). The incorporation of D-amino acids (D-Trp at position 2, D-Phe at position 5) confers resistance to enzymatic degradation, significantly extending biological half-life compared to natural L-peptides.

Alternative Names: Pralmorelin (free base), His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, SKF-110679

3. Mechanism of Action

Primary Mechanism: Ghrelin Receptor Activation

1. GHS-R Binding: GHRP-6 binds to the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor, on pituitary somatotroph cells. This receptor is a GPCR (G protein-coupled receptor) that mediates GH release.

2. Signaling Cascade: Activation triggers phosphatidylinositol (PI) turnover in somatotrophs, initiating intracellular signaling via Gq/11 proteins, leading to calcium mobilization and pulsatile GH secretion.

3. Pulsatile GH Release: GHRP-6 stimulates GH secretion in a pulsatile manner, mimicking the natural pattern of GH release. This pulsatility is critical for physiological GH effects.

4. Ghrelin Mimicry: GHRP-6 mimics the action of ghrelin, the natural endogenous ligand for GHS-R. Ghrelin regulates hunger and GH secretion, explaining GHRP-6's profound appetite-stimulating effects.

Distinction from GHRH

GHRP-6 shares no sequence relation with GHRH (Growth Hormone Releasing Hormone) and functions through a completely different receptor, making it synergistic with GHRH agonists for maximal GH release.

Goal Archetype Integration

Primary Goal Alignment

When GHRP-6 Makes Sense

• Hard gainers struggling to consume sufficient calories for muscle growth
• Bulking phases where appetite stimulation is desired alongside GH benefits
• Recovery from illness/surgery when increased food intake supports healing
• Underweight individuals needing appetite support with anabolic benefits
• Athletes in mass-building phases who want both GH release and hunger drive
• When budget is a consideration - GHRP-6 is typically less expensive than Ipamorelin

When to Choose Something Else

• Fat loss/cutting phases - hunger side effect directly opposes caloric deficit goals → Choose Ipamorelin
• Appetite control is important - GHRP-6's hunger is often described as "agonizing" → Choose Ipamorelin
• Concerned about cortisol/prolactin elevation - these are more pronounced with GHRP-6 → Choose Ipamorelin
• Cleaner hormonal profile desired - Ipamorelin only affects GH, not cortisol/prolactin
• Women with hormonal sensitivity - prolactin elevation risk → Choose Ipamorelin
• Evening dosing when sleep quality matters - hunger may disrupt sleep → Consider alternative timing

GHRP-6 vs. Ipamorelin Decision Matrix

4. Pharmacokinetics

Half-Life

Distribution Half-Life: 7.6 ± 1.9 minutes Elimination Half-Life: 2.5 ± 1.1 hours

• Bi-exponential pharmacokinetics (two-compartment model)
• Some sources report 20-minute half-life, likely reflecting initial distribution phase

Bioavailability

Oral Bioavailability: 0.3% - Extremely low, characteristic of peptide drugs Subcutaneous: High bioavailability (specific % not disclosed) Intranasal: Moderate bioavailability; demonstrated GH-releasing activity

Administration Routes

GHRP-6 has shown GH-releasing activity via:

• Intravenous (100% bioavailability)
• Subcutaneous (preferred route)
• Intranasal (alternative route)
• Oral (poor bioavailability; requires 1000× higher doses)

Dosing Implications

Short half-life necessitates 2–3 times daily dosing for sustained GH elevation.

5. Dosing Protocols

Clinical Trial Dosing

Phase I Pharmacokinetic Study:

• Intravenous: 100, 200, or 400 mcg/kg
• Route: Single IV bolus administration

Pediatric Oral Study:

• Dose: 300 mcg/kg oral administration
• Population: Children with short stature

Subcutaneous Protocols (Research/Anecdotal)

Standard Dosing: 100–300 mcg per injection Optimal Single Dose: 1 mcg/kg body weight Frequency: 2–3 times daily (due to short half-life)

Body Weight-Based Examples:

• 150 lbs (68 kg): 68–100 mcg per dose
• 175 lbs (80 kg): 80–120 mcg per dose
• 200 lbs (91 kg): 91–150 mcg per dose

Timing: Administration 30+ minutes before meals or 2 hours after meals optimizes GH release; avoid high glucose/insulin states.

Important Notes

GHRP-6 is not approved for human use outside licensed clinical research. All subcutaneous protocols are speculative.

Age-Stratified Dosing

Clinical research demonstrates that GH responses to GHRP-6 do not decline significantly with age. In studies comparing young subjects (mean 22 years) to older adults (mean 59.5 years), GH responses to GHRP-6 remained robust in both groups, unlike responses to GHRH which decrease with age.

Key Finding: Research shows impaired GH secretion in late adulthood is a functional and potentially reversible state, and GHRP-6 can restore pulsatile GH release even in older individuals.

Sex-Specific Considerations

Males:

• Standard dosing protocols apply
• Monitor for gynecomastia risk due to prolactin elevation at higher doses
• May benefit from combining with aromatase management if using alongside testosterone

Females:

• Start at lower end of dose range (75-100 mcg)
• Prolactin response more pronounced in presence of estrogen
• Monitor for breast tenderness, menstrual irregularities
• Consider timing around menstrual cycle - appetite effects may be more pronounced during luteal phase
• Pregnancy/breastfeeding: Contraindicated (no safety data)

Saturation Dose Considerations

The saturation dose for GHRP-6 is approximately 100 mcg. Beyond this threshold, receptor saturation occurs with diminishing returns:

Implication: Multiple 100 mcg doses spaced 3+ hours apart provide better GH pulsatility than single large doses.

6. Clinical Research & Evidence

Human Studies

Phase I Pharmacokinetic Trial (2012):

• N=9 male healthy volunteers
• IV administration at 100, 200, 400 mcg/kg
• Results: Bi-exponential pharmacokinetics with distribution half-life 7.6 min, elimination half-life 2.5 hours

Pediatric Oral GH-Releasing Study (1995):

• Oral GHRP-6 at 300 mcg/kg
• Population: Children with short stature
• Results: Demonstrated GH-releasing activity via oral route despite low bioavailability

Human Pituitary Cell Study:

• GHRP-6 stimulated phosphatidylinositol (PI) turnover in human somatotroph cells
• Confirmed direct pituitary GHS-R activation mechanism

Safety Profile from Clinical Research

Phase I study showed GHRP-6 was generally well-tolerated in healthy male volunteers.

Research Limitations

• No large-scale Phase II/III efficacy trials published
• Limited long-term safety data in humans
• Not approved by FDA, EMA, or similar international regulatory bodies

7. Safety Profile

Common Side Effects

Most Prominent: Increased Hunger

• GHRP-6 stimulates the largest hunger increases compared to all other GHRPs
• Users report "agonizing hunger" and binge eating, strong cravings
• Appetite increase occurs within 15–30 minutes of injection

Other Common Effects:

• Flushing, sweating, sleepiness
• Increased GI motility
• Injection site reactions

Water Retention / Fluid Retention:

• Can be serious problem, especially for overweight individuals
• Joints are common sites for water accumulation, compromising movement

GH-Related Side Effects:

• Flu-like symptoms, joint pain, carpal tunnel syndrome
• Headaches, bloating
• Paresthesia (tingling, numbness) in hands/wrists - dose-related, reversible

Hormonal Imbalances:

• Elevated cortisol and prolactin

Serious Adverse Events

FDA Safety Concerns (Sept 2023): FDA identified compounded GHRP-6 products as presenting significant safety risks, including potential immunogenicity due to peptide aggregation for certain administration routes.

Contraindications (Theoretical)

• Active cancer (GH stimulation may promote tumor growth)
• Pregnancy/breastfeeding (unknown fetal/infant effects)
• Diabetes (GH affects insulin sensitivity)
• Existing carpal tunnel syndrome
• Severe water retention disorders

Long-Term Safety: Unknown - Lack of extended clinical trials.

Drug Interactions - Comprehensive

Prescription Medications

Hormone Interactions (Unique to GHRP-6)

Other Compounds (Stacking)

Supplements

Foods/Timing

Bloodwork Impact & Monitoring

Expected Marker Changes

Monitoring Schedule

Red Flags in Labs

Labs + Symptoms Integration

Marker-Based Dose Adjustment

Adjustment by Baseline Markers

Adjustment by Response Markers (4-6 Week Check)

8. Administration & Practical Application

Route: Subcutaneous or intramuscular injection Preferred Route: Subcutaneous; IM may result in slightly quicker release Injection Sites: Abdomen, thigh, upper arm (subcutaneous fat) Reconstitution: Lyophilized powder with bacteriostatic water (typical: 5mg vial + 2.5ml water = 2mg/ml concentration) Injection Technique:

• Use 27–30 gauge insulin needles
• Rotate injection sites
• Maintain sterile technique

Timing:

• Administer on empty stomach (30+ min before meals or 2+ hours after)
• Avoid high glucose/insulin states (blunt GH release)
• 2–3 times daily due to short half-life

9. Storage & Stability

Lyophilized Powder:

• Store at -20°C to -80°C (long-term optimal)
• Refrigerate 2–8°C (short-term acceptable; up to 6 months)
• Protect from light and moisture

Reconstituted Solution:

• Refrigerate 2–8°C immediately after reconstitution
• Use within 28 days with bacteriostatic water
• Use within 3–5 days with sterile water
• Avoid freeze-thaw cycles

Stability Enhancement: D-amino acids confer resistance to proteolytic degradation, improving shelf life vs. natural peptides.

Protocol Integration

Stacking with Other Compounds

Gold Standard Stack: GHRP-6 + CJC-1295 (or Mod GRF 1-29)

Stacks to AVOID

Timing Considerations

Cycling Protocols to Prevent Desensitization

Continuous use of GHRP-6 may lead to desensitization of ghrelin receptors and blunted GH responses over time. Several strategies can mitigate this:

Option 1: Standard Cycling

Option 2: GHRP Rotation (Preferred for Long-Term Use)

Rotate between different GHRPs every 30-45 days to prevent receptor desensitization while maintaining GH optimization:

Note: When rotating TO Ipamorelin, expect loss of appetite stimulation. When rotating FROM Ipamorelin back to GHRP-6, appetite will return.

Option 3: CJC-1295 DAC Combination (Continuous Use)

Adding CJC-1295 with DAC (Drug Affinity Complex) may allow longer continuous use by providing baseline GHRH stimulation that reduces GHRP desensitization:

• CJC-1295 DAC: 2mg twice weekly (provides sustained GHRH)
• GHRP-6: 100 mcg 2-3x daily (provides acute pulses)
• May extend effective use to 3-4 months before needing break

When to Choose GHRP-6 vs. Ipamorelin

Integration with Lifestyle Pillars

Sample Protocol: 8-Week Bulking Stack

Goal: Maximize muscle gain with GH optimization and appetite support

Stack:

• GHRP-6: 100 mcg
• Mod GRF 1-29: 100 mcg
• Combined in same injection

Schedule:

Duration: 8 weeks on, 4 weeks off (or rotate to Ipamorelin)

Expected Outcomes:

• Enhanced appetite supporting caloric surplus
• Improved recovery between training sessions
• Better sleep quality (for most)
• Gradual body composition improvements

11. Product Cross-Reference

Core Peptides Equivalent:

• Product: GHRP-6
• Sizes: 5mg ($20.00 = $4.00/mg); 10mg ($29.00 = $2.90/mg)
• Bulk Pricing: 5–8 units (5% off); 9+ units (10% off)
• Purity: >99%
• Form: Lyophilized powder
• SKU: P-GHRP-6
• Molecular Weight: 873.03 g/mol (verified)
• Free Shipping: Orders $200+

Epiq Aminos: Product availability and pricing to be confirmed via https://orange-shrew-635172.hostingersite.com/

Chemical Validation: Molecular weight and formula match across scientific literature and vendor specifications.

Clinical Insights - Practitioner Dosing

Source: YouTube practitioner interviews

• more of well-being and anti-aging when it comes to the performance side it is recommended to inject 300 micrograms three times a day we've talked about that before those three doses a day can be a hug

Stacking Insights

• thalamus to release growth hormone now the key word there is selective remember that now as we know with synthetic growth hormones it can cause bone and cartilage growth but with the well with most gh
• ember that now as we know with synthetic growth hormones it can cause bone and cartilage growth but with the well with most ghrps you don't get any of that extra [ __ ] it's sarms and ana

12. References & Citations

1. GHRP-6 - Wikipedia
2. Loidi L, et al. Pharmacokinetic study of GHRP-6 in nine male healthy volunteers. Eur J Pharm Sci. 2012.
3. Popovic V, et al. GH-releasing effect of oral GHRP-6 in children with short stature. J Clin Endocrinol Metab. 1995.
4. Adams EF, et al. GHRP-6 stimulates PI turnover in human pituitary somatotroph cells. Endocrinology. 1995.
5. ProSpec - GHRP-6 Product
6. Muscle and Brawn - GHRP-6 Guide
7. Swolverine - GHRP-6 Guide: Benefits, Dosage, Side Effects
8. Swolverine - GHRP-6 For Beginners
9. Peptide Dosages - GHRP-6 10mg Protocol
10. PEP DOSE - GHRP-6 Side Effects
11. MrSupplement - GHRP6: Benefits, Dosage, Side Effects
12. FDA Summary Report - GHRP-6
13. The Safety and Efficacy of Growth Hormone Secretagogues - PMC
14. BodySpec - Peptides for Muscle Growth: Science, Safety, Legal Alternatives
15. Core Peptides - GHRP-6 Product Page

Document Version: 1.0 Last Updated: December 23, 2025 Development Status: Investigational; FDA Enforcement Actions Active For Research and Educational Purposes Only